drugset
drugset / Trial / NCT05923086

Preventing Gastrointestinal Disturbance in Patients After Longitudinal Laparotomy.

NCT05923086 ↗

Phase 2 Recruiting 126 enrolled Orexa BV QPS Holdings LLC · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a multi-center, randomized, double blind, placebo-controlled, phase 2 pilot efficacy study.

Timeline

Start
2024-01-11
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 400 mg Oral

Indications

ileus